Home World News Rucaparib Monotherapy Provides Significant and Durable Long-Term Benefit as First-Line Maintenance for... World News Rucaparib Monotherapy Provides Significant and Durable Long-Term Benefit as First-Line Maintenance for Patients with Advanced Ovarian Cancer with and without HRD By Ogkologos - November 7, 2025 287 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the ATHENA-MONO/GOG-3020/ENGOT-ov45 study Source RELATED ARTICLESMORE FROM AUTHOR Can ctDNA guide treatment intensification in EGFR mutated non-small cell lung cancer? How to select adjuvant endocrine therapy for postmenopausal women with HR-positive early breast cancer? EMA Recommends Extension of Therapeutic Indications for Abiraterone Acetate MOST POPULAR Encouraging Single-Agent Antitumour Activity of Divarasib Across KRAS G12C-positive Tumours September 5, 2023 Girl’s New College Dorm Has Perfect View Of The Hospital Room... September 30, 2021 How to Make the Most of Your Patient Portal During Cancer November 24, 2021 New on NCI’s Websites for September 2020 September 2, 2020 Load more HOT NEWS Exploring Coping Resources to Help with Physical, Practical, and Emotional Challenges... Is AI Ready to Play a Leading Role in Colorectal Cancer... Belzutifan Plus Lenvatinib Improves Outcomes Over Cabozantinib in Patients with Advanced... High HPV Vaccination Coverage in England Associated with a Substantial Reduction...
